CN114929222B - 儿科混悬制剂 - Google Patents
儿科混悬制剂Info
- Publication number
- CN114929222B CN114929222B CN202080069631.2A CN202080069631A CN114929222B CN 114929222 B CN114929222 B CN 114929222B CN 202080069631 A CN202080069631 A CN 202080069631A CN 114929222 B CN114929222 B CN 114929222B
- Authority
- CN
- China
- Prior art keywords
- omeprazole
- mixture
- pharmaceutically acceptable
- sodium
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911035P | 2019-10-04 | 2019-10-04 | |
| US62/911,035 | 2019-10-04 | ||
| US201962911689P | 2019-10-07 | 2019-10-07 | |
| US62/911,689 | 2019-10-07 | ||
| US202063062785P | 2020-08-07 | 2020-08-07 | |
| US63/062,785 | 2020-08-07 | ||
| PCT/IB2020/059280 WO2021064682A1 (en) | 2019-10-04 | 2020-10-02 | Pediatric suspension formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114929222A CN114929222A (zh) | 2022-08-19 |
| CN114929222B true CN114929222B (zh) | 2025-10-28 |
Family
ID=72744602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080069631.2A Active CN114929222B (zh) | 2019-10-04 | 2020-10-02 | 儿科混悬制剂 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11826359B2 (https=) |
| EP (2) | EP4331572A3 (https=) |
| JP (2) | JP7801996B2 (https=) |
| KR (1) | KR20220103711A (https=) |
| CN (1) | CN114929222B (https=) |
| AU (1) | AU2020358472B2 (https=) |
| CA (1) | CA3153555A1 (https=) |
| ES (1) | ES2974364T3 (https=) |
| IE (1) | IE20200221A1 (https=) |
| IL (1) | IL291778B2 (https=) |
| MX (1) | MX2022003917A (https=) |
| PH (1) | PH12022550798A1 (https=) |
| TW (1) | TW202126301A (https=) |
| WO (1) | WO2021064682A1 (https=) |
| ZA (1) | ZA202203563B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202126301A (zh) | 2019-10-04 | 2021-07-16 | 愛爾蘭商席歐拉斯製藥有限公司 | 小兒懸浮調配物 |
| GB2631129A (en) * | 2023-06-23 | 2024-12-25 | Orbit Pharma Ltd | A powder composition for oral suspension of proton pump inhibitors and the method of preparing the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016178132A1 (en) * | 2015-05-01 | 2016-11-10 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for extended release suspension compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US20020192299A1 (en) | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| CA2448997A1 (en) * | 2001-05-31 | 2002-12-05 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| US20050098526A1 (en) * | 2003-11-06 | 2005-05-12 | Robertino Catalin | Two bottles/containers in one |
| WO2005076987A2 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| ES2283172B1 (es) * | 2005-01-21 | 2008-08-16 | Universidad De Granada | Suspension extemporanea de omeprazol para via oral. |
| AR056062A1 (es) * | 2006-06-05 | 2007-09-19 | Bago Sa Labor | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
| EP2068854A2 (en) | 2006-07-29 | 2009-06-17 | Graceway Pharmaceuticals, LLC | Business method to treat and/or prevent a gastric acid disorder with a proton pump inhibitor (ppi) and a cholinergic agonist to induce rapid onset of ppi action with or without food |
| EP2068841B1 (en) | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| JP2011512416A (ja) | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
| JP5248614B2 (ja) | 2008-09-01 | 2013-07-31 | 株式会社フレッシュ | キャップおよびキャップ付き容器 |
| PL2827843T3 (pl) * | 2012-03-20 | 2016-11-30 | Sposób wytwarzania dojelitowych alginianowych mikrokapsułek poprzez żelowanie jonowe zawierających diklofenak lub jedną z jego soli oraz zawierającej je wielocząsteczkowej kompozycji farmaceutycznej | |
| GB2513172A (en) | 2013-04-18 | 2014-10-22 | Nupharm Lab Ltd | Liquid dosage form and delivery system |
| BR112017001968A2 (pt) | 2014-07-30 | 2017-11-21 | Sun Pharmaceutical Ind Ltd | embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses |
| US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
| US11207307B2 (en) | 2016-06-16 | 2021-12-28 | Azurity Pharmaceuticals, Inc. | Composition and method for proton pump inhibitor suspension |
| US10137111B2 (en) * | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
| TW202126301A (zh) | 2019-10-04 | 2021-07-16 | 愛爾蘭商席歐拉斯製藥有限公司 | 小兒懸浮調配物 |
-
2020
- 2020-09-30 TW TW109134317A patent/TW202126301A/zh unknown
- 2020-10-02 EP EP23210683.1A patent/EP4331572A3/en active Pending
- 2020-10-02 PH PH1/2022/550798A patent/PH12022550798A1/en unknown
- 2020-10-02 IL IL291778A patent/IL291778B2/en unknown
- 2020-10-02 WO PCT/IB2020/059280 patent/WO2021064682A1/en not_active Ceased
- 2020-10-02 AU AU2020358472A patent/AU2020358472B2/en active Active
- 2020-10-02 ES ES20199781T patent/ES2974364T3/es active Active
- 2020-10-02 KR KR1020227015146A patent/KR20220103711A/ko active Pending
- 2020-10-02 CN CN202080069631.2A patent/CN114929222B/zh active Active
- 2020-10-02 JP JP2022516686A patent/JP7801996B2/ja active Active
- 2020-10-02 US US17/061,630 patent/US11826359B2/en active Active
- 2020-10-02 EP EP20199781.4A patent/EP3799861B1/en active Active
- 2020-10-02 CA CA3153555A patent/CA3153555A1/en active Pending
- 2020-10-02 MX MX2022003917A patent/MX2022003917A/es unknown
- 2020-10-02 IE IE20200221A patent/IE20200221A1/en not_active Application Discontinuation
-
2022
- 2022-03-28 ZA ZA2022/03563A patent/ZA202203563B/en unknown
-
2023
- 2023-03-13 US US18/182,797 patent/US12465600B2/en active Active
-
2025
- 2025-09-12 JP JP2025152489A patent/JP2025170126A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016178132A1 (en) * | 2015-05-01 | 2016-11-10 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for extended release suspension compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| US11826359B2 (en) | 2023-11-28 |
| AU2020358472B2 (en) | 2026-01-15 |
| US20230390266A1 (en) | 2023-12-07 |
| WO2021064682A1 (en) | 2021-04-08 |
| JP7801996B2 (ja) | 2026-01-19 |
| IE20200221A1 (en) | 2022-08-17 |
| EP4331572A3 (en) | 2024-06-05 |
| KR20220103711A (ko) | 2022-07-22 |
| CA3153555A1 (en) | 2021-04-08 |
| AU2020358472A1 (en) | 2022-04-07 |
| CN114929222A (zh) | 2022-08-19 |
| JP2025170126A (ja) | 2025-11-14 |
| ZA202203563B (en) | 2025-07-30 |
| EP4331572A2 (en) | 2024-03-06 |
| IL291778A (en) | 2022-06-01 |
| ES2974364T3 (es) | 2024-06-27 |
| EP3799861A1 (en) | 2021-04-07 |
| IL291778B2 (en) | 2024-09-01 |
| MX2022003917A (es) | 2022-06-14 |
| IL291778B1 (en) | 2024-05-01 |
| EP3799861B1 (en) | 2023-11-22 |
| US12465600B2 (en) | 2025-11-11 |
| US20210100784A1 (en) | 2021-04-08 |
| PH12022550798A1 (en) | 2023-09-18 |
| JP2022550690A (ja) | 2022-12-05 |
| TW202126301A (zh) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1194153B1 (en) | Taste masked pharmaceutical liquid formulations | |
| JP2025170126A (ja) | 小児懸濁液製剤 | |
| JPH0482832A (ja) | 医薬組成物 | |
| BRPI0820308B1 (pt) | Composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido | |
| WO2005117870A2 (en) | Combination of proton pump inhibitor, buffering agent, and prokinetic agent | |
| HU211285A9 (en) | Oral dosing formulations of dideoxy purine nucleosides | |
| IL118091A (en) | Preparations for use in the treatment of bacterial infections in children | |
| US20140311929A1 (en) | Liquid dosage form and delivery system | |
| MX2007006722A (es) | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion. | |
| CN115227658A (zh) | 一种氨己烯酸固体制剂组合物 | |
| WO2020212898A1 (en) | Pharmaceutical oral liquid solution of ivacaftor | |
| US20020099044A1 (en) | Composition comprising amoxycillin and clavulanic acid | |
| US20240315956A1 (en) | Method of production of the composition of cyclooxygenase-2 (cox-2) inhibitors | |
| WO2012066401A1 (en) | Stable oral pharmaceutical compositions of montelukast | |
| CA2220103C (en) | Composition comprising amoxycillin and clavulanic acid | |
| SI20058A (sl) | Farmacevtske oblike |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |